Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.1 USD | +2.33% | +0.65% | -45.38% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.38% | 2.82B | |
+1.77% | 42.86B | |
+46.90% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating